97 drugs negotiated to enter the medical insurance catalog, with a 60.7% decrease in imported drugs, the lowest in the world!

Today (November 28), at 10 a.m., the state health insurance bureau held a press conference to introduce the list of drugs to be negotiated and admitted by the state health insurance in 2019 A total of 150 drugs were negotiated and 97 varieties were negotiated, all of which were included in the category B Medical Insurance catalogue ◆ 70 of the 119 new drugs were negotiated successfully, with an average price decrease of 60.7% ◆ 27 of the 31 non new drugs were successfully renewed, with an average price decrease of 26.4% Most of the drugs successfully negotiated in this negotiation are newly marketed drugs with high clinical value in recent years, involving more than 10 clinical treatment fields such as cancer, rare disease, hepatitis, diabetes, MDR-TB, rheumatism immunity, cardio cerebrovascular, digestion, etc From the perspective of key areas, all 5 basic drugs were negotiated successfully, 22 anticancer drugs, 7 drugs for rare diseases, 14 drugs for chronic diseases (including diabetes, hepatitis B, rheumatoid arthritis, etc.), 4 drugs for children were negotiated successfully, and the directory structure was further optimized The average decrease of tumor and diabetes drugs was about 65%, and the average decrease of three kinds of hepatitis C drugs was more than 85% In the negotiation of hepatitis C treatment and drug use, the price of six hepatitis C drugs is high In order to guide enterprises to reduce the price to a reasonable range, a competitive negotiation method was adopted, allowing two drug companies to be included in the catalogue with a lower course price The state health insurance bureau promised not to include new similar drugs within two years The national basic medical insurance system guarantees the people's livelihood and always hopes to make the people look up to the disease with lower drug prices, which is essentially contrary to the pursuit of benefits by enterprises It is a sales strategy for enterprises to trade quantity for price reduction for access This is a certain trade-off for pharmaceutical enterprises - winning a bid is not necessarily good, and those who do not win a bid cannot be said to be totally bad In the process of deciding whether to exchange quantity for price, the enterprise should also consider the stage of the product, the therapeutic effect, and the company's business strategy This negotiation on medical insurance catalogue is the largest since the establishment of medical insurance system in China, and has achieved many results A number of world-famous "noble drugs" have offered "civilian price", and imported drugs have basically given the lowest price in the world According to the conservative estimate of the National Health Insurance Bureau, through negotiation of price reduction and medical insurance reimbursement, the individual burden level of patients will be reduced to less than 20% in the future, and the individual drugs will be reduced to less than 5% After this round of adjustment, there are 2709 drugs included in the catalogue of drugs for national basic medical insurance, work injury insurance and maternity insurance in 2019 Compared with the 2017 edition, 218 drugs were transferred in, 154 drugs were transferred out, with a net increase of 64.